Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    600 result(s) found for: Chronic Obstructive Pulmonary Disease (COPD). Displaying page 6 of 30.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2006-005819-10 Sponsor Protocol Number: KKS-95 Start Date*: 2007-12-07
    Sponsor Name:Philipps-University Marburg
    Full Title: Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation -TIBROMUC-
    Medical condition: Anticholinergic bronchodilators, such as ipratropium bromide, may be used in combination with beta adrenergic agonists as SAlbutamol to produce bronchodilation in excess of that achieved by either ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004818-28 Sponsor Protocol Number: CNVA237A2320 Start Date*: 2015-07-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstruct...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) HU (Completed) BE (Completed) SE (Completed) GB (Completed) BG (Completed) PL (Completed) RO (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000179-38 Sponsor Protocol Number: ESR-21-21168 Start Date*: 2022-04-28
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001933-84 Sponsor Protocol Number: 1222.13 Start Date*: 2008-11-18
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuat...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000663-42 Sponsor Protocol Number: CQAB149B2335SE Start Date*: 2008-06-03
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Extensión de 26 semanas del estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, con grupos paralelos y diseño adaptativo, de 26 semanas de tratamiento, para evaluar la segurid...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004369-29 Sponsor Protocol Number: 206854 Start Date*: 2018-04-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGYTM ELLIPTATM) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001585-14 Sponsor Protocol Number: EPJ-2012 Start Date*: 2013-01-10
    Sponsor Name:FISEVI
    Full Title: Effect of the elimination of colonization by Pneumocystis jirovecii on inflammatory response in patients with chronic obstructive pulmonary disease
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10064107 Pneumocystis jiroveci infection PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018987-17 Sponsor Protocol Number: EP-101-02 Start Date*: 2010-06-22
    Sponsor Name:Elevation Pharmaceuticals, Inc.
    Full Title: Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single Dose, 6-Way Crossover Study to Assess the Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebulizer in Patients with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003962-16 Sponsor Protocol Number: D3540C00005 Start Date*: 2007-11-27
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic O...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002966-38 Sponsor Protocol Number: CCD-01535BC1-02 Start Date*: 2013-11-20
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A PHASE II, PARTIAL-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 5-WAY CROSS-OVER CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE PHARMACODYNAMICS OF BDP/B17MP AND FORMOTEROL ACROSS TWO DIFFERENT DOSE LEVELS...
    Medical condition: COPD patients
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005909-19 Sponsor Protocol Number: PAW002 Start Date*: 2009-01-29
    Sponsor Name:The University of Dundee
    Full Title: Does extra fine HFA-BDP suppress small airways inflammation in COPD?
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004431-38 Sponsor Protocol Number: P15099 Start Date*: 2009-02-20
    Sponsor Name:Imperial College
    Full Title: ACE inhibition and mechanisms of skeletal muscle weakness in COPD
    Medical condition: Chronic obstructive pulmonary disease patients who have skeletal muscle weakness.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013686-26 Sponsor Protocol Number: CQAB149BDE01 Start Date*: 2009-10-16
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate ...
    Medical condition: moderate chonic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005534-20 Sponsor Protocol Number: 05102006 Start Date*: 2008-01-24
    Sponsor Name:Imperial College London
    Full Title: Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD) of different severity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016251-21 Sponsor Protocol Number: 205.458 Start Date*: 2010-10-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000116-81 Sponsor Protocol Number: SIL-COPD-01 Start Date*: 2007-05-28
    Sponsor Name:Hospital Clinic Barcelona
    Full Title: Estudio de los efectos agudos de la administración de una dosis única de sildenafilo de 20 o 40 mg sobre el intercambio de gases y la hemodinámica pulmonar, en reposo y durante el esfuerzo, en paci...
    Medical condition: EPOC e hipertensión pulmonar asociada
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010668-40 Sponsor Protocol Number: 1237.5 Start Date*: 2011-07-29
    Sponsor Name:Boehringer Ingelheim bv [...]
    1. Boehringer Ingelheim bv
    2. Boehringer Ingelheim bv
    Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) PT (Completed) SI (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001586-24 Sponsor Protocol Number: Start Date*: 2017-08-07
    Sponsor Name:University of Oxford
    Full Title: Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial
    Medical condition: Chronic obstructive pulmonary disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008447-26 Sponsor Protocol Number: CQAB149B2351 Start Date*: 2009-03-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) HU (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 09:31:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA